首頁 > 市場調查報告書 > 醫療設備

藥物遞輸設備

市場調查報告書

商品編碼

1803528

Lecanemab 注射劑市場：2025-2030 年全球預測（按患者分期、患者年齡、最終用戶和分銷管道）

Lecanemab Injection Market by Patient Stage, Patient Age, End User, Distribution Channel - Global Forecast 2025-2030

出版日期: 2025年08月28日 | 出版商:

360iResearch | 英文 194 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄圖表

預計 2024 年 Lecanemab 注射劑市場規模將達到 5.1305 億美元，2025 年成長至 5.4173 億美元，到 2030 年將達到 7.1563 億美元，複合年成長率為 5.70%。

主要市場統計數據
基準年2024年	5.1305億美元
預計2025年	5.4173億美元
預測年份 2030	7.1563億美元
複合年成長率（%）	5.70%

揭示樂卡尼單抗注射液在阿茲海默症治療中的重要角色及其對全球醫療網路治療範式的影響

阿茲海默症仍然是神經病學領域最艱鉅的挑戰之一，推動著緩解疾病療法的持續創新。 Lecanemab 是一種可注射的抗澱粉樣BETA蛋白原纖維抗體，它透過針對認知衰退早期的澱粉樣蛋白聚集，代表著模式轉移。其選擇性結合原纖維的機制，為尋求超越症狀治療的干涉措施的臨床醫生和患者帶來了新的希望。

探索Lecanemab創新和以患者為中心的全新護理策略為阿茲海默症治療帶來的變革

隨著注射用lecanemab從臨床試驗走向臨床實踐，阿茲海默症的治療模式正在發生重大轉變。澱粉樣蛋白清除和認知穩定性的療效數據促使人們重新審視治療目標和患者選擇標準。因此，目前的治療流程優先考慮生物標記主導的通路，使輕度認知障礙患者能夠接受快速評估和潛在的抗體治療。

評估2025年美國關稅對阿茲海默症生技藥品供應鏈的累積影響：監管格局與成本結構

美國關稅將於2025年生效，預計將影響包括抗澱粉樣蛋白抗體在內的生物製藥的供應動態。對原料藥和成品藥的進口關稅上調可能會增加依賴全球生產網路的製藥公司的生產成本。為此，製藥公司正在評估本地生產能力和替代籌資策略，以減輕關稅的影響。

從患者階段、最終用戶和分銷管道細分中獲得客製化見解，以揭示老年失智症的失智症採用模式

對於阿茲海默症的治療，對患者群體進行細分可以揭示重要的見解，從而指導有針對性的干涉措施。以疾病分期評估，早期阿茲海默症患者對抗體治療的反應通常優於中度認知衰退患者，這凸顯了及時診斷和開始治療的重要性。同樣，輕度認知功能障礙患者是關鍵族群，預防策略可能帶來顯著的長期益處。

檢驗美洲、歐洲、中東和非洲以及亞太市場阿茲海默症治療發展的不同區域動態

阿茲海默症治療應用的區域動態揭示了由醫療基礎設施、報銷政策和人口統計特徵塑造的微妙趨勢。在美洲，支付方和醫療服務提供者正在率先採用基於療效的報銷模式，並透過專門的記憶護理網路擴大醫療覆蓋範圍。早期採用此療法的地區正在神經科科診所旁開設輸液中心，以滿足日益成長的抗體治療需求。

重點介紹推動阿茲海默症研究進步和先進治療解決方案競爭差異化的關鍵生物製藥創新者

領先的生物製藥公司透過強大的研發管線、策略聯盟和有針對性的商業化努力，推動了阿茲海默症的研究。在Lecanemab的開發中，雙方的開創性合作開創了共用神經退化生物學和臨床業務專業知識的共同開發模式。同時，競爭對手也在尋求其他靶點，例如Tau聚集和神經發炎路徑。

醫療保健相關人員最佳化 Lecanemab 整合的策略行動計劃，旨在改善患者療效並鞏固市場地位

醫療保健相關人員應積極調整治療途徑，以最佳化Lecanemab在多學科照護框架內的整合。建立專業的輸液單元並培養專業的護理團隊可以增強病人安全並簡化行政工作流程。此外，儘早與付款方溝通，協商基於價值的契約，可以降低報銷的不確定性，並展現對患者療效的承諾。

利用一手和二手研究及分析方法的綜合研究框架，確保對阿茲海默症治療評估具有可靠的洞察力

我們的調查方法融合了嚴謹的原始研究和二手資料收集，以確保基於實證證據和行業最佳實踐的洞察。原始研究包括對神經科、輸液中心主任、付款方代表和監管專家的深入訪談，提供有關治療方法採用和營運挑戰的第一手觀點。

老年失智症失智症治療的關鍵發現和未來考慮總結：確定 lecanemab 和新治療方式的前進道路

本執行摘要綜合了臨床、監管和營運領域的證據，重點介紹了Lecanemab注射液如何重新定義阿茲海默症的治療途徑。早期療育策略、自適應授權模式以及以患者為中心的數位化解決方案，標誌著我們正朝著更個人化和積極主動的治療模式轉變。

擴大主要市場的報銷途徑將促進 lecanemab 的商業化上市
血漿生物標記的整合加速了 lecanemab 治療患者的識別
真實世界數據揭示了安全性和有效性趨勢，這將影響臨床醫生對 lecanemab 的採用
聯合生產舉措解決了全球 lecanemab 推廣中的供應限制
生物相似藥產品線瞄準 Lecanemab專利到期，競爭格局加劇
付款人談判策略不斷發展，以解決阿茲海默症症 Lecanemab 療法的高成本問題
亞太地區新法規結構有利於有條件核准lecanemab 用於治療阿茲海默症
融入臨床實踐的數位監測工具可提高阿茲海默症患者對 lecanemab 治療的長期依從性
病患權益團體正在影響政策變化，以改善醫療服務不足地區獲得 lecanemab 的機會。
衛生技術評估結合真實世界證據，重新定義Lecanemab在阿茲海默症治療中的價值提案

第6章市場洞察

波特五力分析
PESTEL分析

第7章 2025年美國關稅的累積影響

8. Lecanemab 注射液市場（依病患階段）

早期阿茲海默症
輕度認知障礙
中度阿茲海默症

9. Lecanemab 注射劑市場（依患者年齡）

60-70歲
71至80歲
81歲或以上

第 10 章 Lecanemab 注射劑市場（按最終用戶分類）

家庭醫療保健
醫院
長期照護機構
專科診所

第 11 章 Lecanemab 注射液市場（依通路）

醫院藥房
網路藥局
零售藥局

12.美洲Lecanemab注射液市場

美國
加拿大
墨西哥
巴西
阿根廷

13. 歐洲、中東和非洲Lecanemab注射液市場

英國
德國
法國
俄羅斯
義大利
西班牙
阿拉伯聯合大公國
沙烏地阿拉伯
南非
丹麥
荷蘭
卡達
芬蘭
瑞典
奈及利亞
埃及
土耳其
以色列
挪威
波蘭
瑞士

14. 亞太地區Lecanemab注射液市場

中國
印度
日本
澳洲
韓國
印尼
泰國
菲律賓
馬來西亞
新加坡
越南
台灣

第15章競爭格局

2024年市場佔有率分析
2024年FPNV定位矩陣
競爭分析
- Eisai Co., Ltd.
- BioArctic AB
- Biogen Inc.
- Soleo Health

第16章研究人工智慧

第17章研究統計

第18章研究聯絡人

第19章研究報導

第20章附錄

簡介目錄圖表

Product Code: MRR-F774F6336BCD

The Lecanemab Injection Market was valued at USD 513.05 million in 2024 and is projected to grow to USD 541.73 million in 2025, with a CAGR of 5.70%, reaching USD 715.63 million by 2030.

KEY MARKET STATISTICS
Base Year [2024]	USD 513.05 million
Estimated Year [2025]	USD 541.73 million
Forecast Year [2030]	USD 715.63 million
CAGR (%)	5.70%

Unveiling the Critical Role of Lecanemab Injection in Alzheimer's Care and Its Implications for Treatment Paradigms Across Global Healthcare Networks

Alzheimer's disease continues to pose one of the most formidable challenges in neurology, driving relentless innovation toward disease-modifying treatments. Lecanemab injection, an anti-amyloid beta protofibril antibody, represents a paradigm shift by targeting amyloid aggregation in early stages of cognitive decline. Its mechanism of selectively binding protofibrils has brought renewed hope to clinicians and patients seeking interventions beyond symptomatic relief.

Since receiving regulatory clearance for early Alzheimer's disease, Lecanemab has sparked discourse around treatment timing, biomarker screening, and infusion protocols. Clinicians emphasize the importance of early intervention, given that neurodegeneration advances long before clinical symptoms emerge. Consequently, diagnosis frameworks are adapting to integrate advanced PET imaging and fluid biomarkers, ensuring eligible patients may benefit from antibody therapy at optimal stages.

Moreover, healthcare systems are exploring infusion centers, specialized memory clinics, and coordinated care pathways to manage administration and monitoring. These developments illustrate a shift from primary care-led management toward multidisciplinary teams that encompass neurologists, radiologists, and dementia specialists. As a result, the introduction of Lecanemab has catalyzed structural changes in care delivery models, emphasizing early detection and personalized treatment plans.

Exploring Transformative Shifts in Alzheimer's Therapeutics Landscape Driven by Lecanemab Innovations and Emerging Patient-Centric Care Strategies

The Alzheimer's treatment landscape has undergone transformative shifts as Lecanemab injection moves from clinical trials into real-world practice. Its efficacy data, demonstrating amyloid clearance and cognitive stabilization, has stimulated a reexamination of therapeutic goals and patient selection criteria. Consequently, treatment algorithms now prioritize biomarker-driven pathways, ensuring individuals with mild cognitive impairment receive prompt evaluation and potential antibody therapy.

Furthermore, regulatory agencies have introduced accelerated approval frameworks and managed-access programs to expedite availability. These initiatives underscore a broader trend toward adaptive licensing, wherein post-approval studies inform label modifications and access expansions. At the same time, payers are evaluating innovative reimbursement models that tie payment to clinical outcomes, reflecting a shift toward value-based care.

Meanwhile, patient advocacy groups and social support organizations have intensified outreach to educate communities about early warning signs and diagnostic resources. This patient-centric movement has fostered digital health solutions including remote cognitive assessments and telemedicine consultations. As these complementary innovations gain traction, they are poised to further reshape how antibodies like Lecanemab integrate into holistic Alzheimer's care.

Assessing the Cumulative Impact of United States Tariffs in 2025 on Alzheimer's Biologics Supply Chains Regulatory Landscape and Cost Structures

United States tariffs set to take effect in 2025 are expected to influence the supply dynamics of biologic therapies including anti-amyloid antibodies. Increased import duties on active pharmaceutical ingredients and finished formulations may elevate manufacturing costs for providers reliant on global production networks. In response, pharmaceutical companies are evaluating localized manufacturing capabilities and alternative sourcing strategies to mitigate tariff impacts.

Moreover, infusion centers and hospital pharmacies are assessing potential cost adjustments and inventory management plans. Some stakeholders plan to negotiate long-term contracts that lock in favorable pricing before tariffs are implemented. Others are exploring strategic stockpiling of key reagents and leveraging contract manufacturing organizations located in tariff-exempt jurisdictions.

At the same time, regulatory compliance teams are working to align procurement practices with evolving trade regulations, ensuring uninterrupted access to necessary infusion supplies and cold chain logistics. As a result, collaborative efforts between supply chain specialists, legal advisors, and clinical operations units have intensified. These measures aim to preserve treatment continuity for patients while maintaining financial sustainability across the distribution network.

Uncovering Tailored Insights from Patient Stage Age End User and Distribution Channel Segmentation to Illuminate Alzheimer's Treatment Adoption Patterns

In Alzheimer's therapeutics, segmenting the patient population reveals critical insights that guide targeted interventions. When evaluated by disease stage, individuals diagnosed with early Alzheimer's disease often demonstrate greater responsiveness to antibody therapy compared to those with moderate cognitive decline, highlighting the importance of prompt diagnosis and initiation of treatment. Similarly, those presenting mild cognitive impairment occupy a pivotal position where preventative strategies may yield substantial long-term benefits.

Age-based segmentation further refines treatment considerations. Patients within the 60-70-year cohort tend to exhibit fewer comorbidities and better tolerability profiles, whereas those aged 71-80 require more rigorous safety monitoring. In the oldest group, 81 years and above, treatment decisions frequently hinge on holistic assessments that account for frailty and quality-of-life priorities.

End-user environments shape care delivery and resource allocation. Home healthcare services must adapt infusion protocols for ambulatory settings, while hospital and specialty clinics focus on centralized infusion suites and neurologist-led monitoring. Long term care facilities, conversely, emphasize interdisciplinary collaboration to integrate antibody therapy into established dementia care regimens.

Distribution channel analysis underscores the evolving role of hospital pharmacies as primary infusion suppliers, with online pharmacies emerging for at-home administration support and retail pharmacies serving adjunctive medication needs. These varied channels collectively enhance accessibility and streamline therapy initiation across diverse care environments.

Examining the Diverse Regional Dynamics of Alzheimer's Treatment Developments across Americas Europe Middle East Africa and Asia-Pacific Markets

Regional dynamics in Alzheimer's therapy adoption reveal nuanced trends shaped by healthcare infrastructure, reimbursement policies, and demographic profiles. In the Americas, payers and providers are pioneering outcome-based reimbursement models and expanding access through dedicated memory care networks. Early adopter regions have established infusion centers alongside neurology clinics to accommodate growing demand for antibody treatments.

Meanwhile, Europe, the Middle East, and Africa exhibit heterogeneous trajectories. Western European nations with centralized health systems have integrated amyloid imaging and infusion services into national dementia strategies, whereas emerging markets in the region are building capacity through public-private partnerships and targeted training programs for neurologists. Reimbursement negotiations often hinge on real-world evidence, with health technology assessment bodies requiring post-launch data to inform coverage decisions.

In Asia-Pacific, governments and industry leaders are collaborating to accelerate clinical trial participation and expand biomarker screening. Countries with aging populations are investing in diagnostic infrastructure, while regional hubs are emerging as manufacturing centers for monoclonal antibody formulations. Throughout the region, cross-border alliances and knowledge-sharing forums are fostering rapid dissemination of best practices in infusion management and patient monitoring.

Highlighting Leading Biopharmaceutical Innovators Driving Alzheimer's Research Progress and Competitive Differentiation in Advanced Therapeutic Solutions

Leading biopharmaceutical organizations have advanced Alzheimer's research through robust pipelines, strategic alliances, and targeted commercialization efforts. The pioneering collaboration behind the development of Lecanemab has set a precedent for co-development models that leverage shared expertise in neurodegenerative biology and clinical operations. At the same time, competitors are pursuing alternative targets such as tau protein aggregation and neuroinflammation pathways.

Several established players have diversified their portfolios with complementary therapies, including small molecule candidates and combination regimens designed to address downstream neurodegenerative cascades. New entrants are leveraging artificial intelligence to accelerate target discovery and optimize antibody engineering. Meanwhile, contract research organizations support adaptive clinical trial designs that facilitate rapid dose optimization and endpoint validation.

Together, these companies are shaping a competitive landscape characterized by both differentiation and convergence. Differentiation arises from proprietary biomarker strategies and novel delivery mechanisms, whereas convergence is seen in cross-licensing agreements and joint ventures aimed at expanding global manufacturing capacity. As a result, stakeholders across the value chain continue to prioritize collaborative innovation to expedite therapeutic breakthroughs.

Strategic Action Plans for Healthcare Stakeholders to Optimize Lecanemab Integration Enhance Patient Outcomes and Strengthen Market Positioning

Healthcare stakeholders should proactively align care pathways to optimize Lecanemab integration within multidisciplinary treatment frameworks. Establishing specialized infusion units and training dedicated nursing teams can enhance patient safety and streamline administration workflows. In addition, early engagement with payers to negotiate value-based agreements will mitigate reimbursement uncertainty and demonstrate commitment to patient outcomes.

Moreover, providers and life sciences organizations should invest in digital platforms that facilitate remote cognitive monitoring and patient education. Leveraging telehealth capabilities can expand access for individuals in underserved regions and improve adherence through real-time support. Simultaneously, forging alliances with geriatric and primary care networks will bolster referral pathways and accelerate diagnosis rates.

Furthermore, manufacturing partners and logistics providers must implement robust supply chain visibility tools to anticipate tariff-related disruptions. Scenario planning exercises and strategic procurement agreements will safeguard inventory levels and control cost volatility. Collectively, these strategic actions will strengthen market positioning, foster sustainable growth, and ultimately enhance the standard of care for individuals affected by Alzheimer's disease.

Comprehensive Research Framework Leveraging Primary Secondary Data and Analytical Approaches to Ensure Robust Insights for Alzheimer's Therapeutic Evaluation

Our research methodology integrates rigorous primary and secondary data collection to ensure insights are grounded in empirical evidence and industry best practices. Primary research includes detailed interviews with neurologists, infusion center directors, payer representatives, and regulatory experts who provide first-hand perspectives on therapeutic adoption and operational challenges.

Secondary research draws upon peer-reviewed journals, clinical trial registries, regulatory documents, and publicly available financial disclosures. We employ a systematic literature review process, followed by data triangulation techniques to validate findings across multiple sources. This approach minimizes bias and enhances the reliability of market dynamics interpretation.

Analytical frameworks such as SWOT and Porter's Five Forces are adapted to evaluate competitive positioning and emerging opportunities. In addition, geographic information system analyses support regional insights by mapping infrastructure density and demographic trends. Finally, our quality assurance protocols include cross-validation with external experts and iterative feedback loops, resulting in a comprehensive and dependable assessment of the Alzheimer's therapeutic landscape.

Summarizing Key Learnings and Future Considerations in Alzheimer's Therapeutics Illuminating the Path Forward for Lecanemab and Emerging Treatment Modalities

By consolidating evidence across clinical, regulatory, and operational domains, this executive summary highlights how Lecanemab injection is redefining Alzheimer's care pathways. Early intervention strategies, adaptive licensing models, and patient-centric digital solutions collectively demonstrate a shift toward more personalized and proactive treatment paradigms.

Looking ahead, the integration of real-world data and biomarker validation studies will further refine patient selection criteria and optimize therapeutic outcomes. Moreover, continued collaboration between industry, academia, and healthcare systems promises to accelerate the development of complementary therapies that target diverse aspects of Alzheimer's pathology.

Ultimately, sustained progress will depend on orchestrated efforts across the value chain-from clinical trial innovation and payer partnerships to supply chain resilience and provider education. These converging initiatives set the stage for transformative improvements in patient quality of life and healthcare efficiency.

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

4.1. Introduction
4.2. Market Sizing & Forecasting

5. Market Dynamics

5.1. Lecanemab commercial launch driven by expanded reimbursement pathways across major markets
5.2. Integration of plasma biomarkers accelerates patient identification for lecanemab treatment
5.3. Real-world data reveals safety and efficacy trends shaping lecanemab adoption among clinicians
5.4. Collaborative manufacturing initiatives address supply constraints for global lecanemab rollout
5.5. Competitive landscape intensifies as biosimilar pipelines target lecanemab patent expiration window
5.6. Payer negotiation strategies evolve to accommodate high-cost lecanemab therapy in Alzheimer's care
5.7. Emerging regulatory frameworks in Asia-Pacific expedite conditional approvals for lecanemab in Alzheimer's treatment landscapes
5.8. Digital monitoring tools integrated into clinical practice boost long-term adherence rates for lecanemab therapy in Alzheimer's patients
5.9. Patient advocacy groups influence policy changes to improve lecanemab access across underserved communities
5.10. Health technology assessments incorporate real-world evidence to redefine lecanemab value proposition in Alzheimer's care

6. Market Insights

6.1. Porter's Five Forces Analysis
6.2. PESTLE Analysis

7. Cumulative Impact of United States Tariffs 2025

8. Lecanemab Injection Market, by Patient Stage

8.1. Introduction
8.2. Early Alzheimer's Disease
8.3. Mild Cognitive Impairment
8.4. Moderate Alzheimer's Disease

9. Lecanemab Injection Market, by Patient Age

9.1. Introduction
9.2. 60-70 years
9.3. 71-80 years
9.4. 81+ years

10. Lecanemab Injection Market, by End User

10.1. Introduction
10.2. Home Healthcare
10.3. Hospitals
10.4. Long Term Care Facilities
10.5. Specialty Clinics

11. Lecanemab Injection Market, by Distribution Channel

11.1. Introduction
11.2. Hospital Pharmacies
11.3. Online Pharmacies
11.4. Retail Pharmacies

12. Americas Lecanemab Injection Market

12.1. Introduction
12.2. United States
12.3. Canada
12.4. Mexico
12.5. Brazil
12.6. Argentina

13. Europe, Middle East & Africa Lecanemab Injection Market

13.1. Introduction
13.2. United Kingdom
13.3. Germany
13.4. France
13.5. Russia
13.6. Italy
13.7. Spain
13.8. United Arab Emirates
13.9. Saudi Arabia
13.10. South Africa
13.11. Denmark
13.12. Netherlands
13.13. Qatar
13.14. Finland
13.15. Sweden
13.16. Nigeria
13.17. Egypt
13.18. Turkey
13.19. Israel
13.20. Norway
13.21. Poland
13.22. Switzerland

14. Asia-Pacific Lecanemab Injection Market

14.1. Introduction
14.2. China
14.3. India
14.4. Japan
14.5. Australia
14.6. South Korea
14.7. Indonesia
14.8. Thailand
14.9. Philippines
14.10. Malaysia
14.11. Singapore
14.12. Vietnam
14.13. Taiwan

15. Competitive Landscape

15.1. Market Share Analysis, 2024
15.2. FPNV Positioning Matrix, 2024
15.3. Competitive Analysis
- 15.3.1. Eisai Co., Ltd.
- 15.3.2. BioArctic AB
- 15.3.3. Biogen Inc.
- 15.3.4. Soleo Health

16. ResearchAI

17. ResearchStatistics

18. ResearchContacts

19. ResearchArticles

20. Appendix

簡介目錄圖表

LIST OF FIGURES

FIGURE 1. LECANEMAB INJECTION MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL LECANEMAB INJECTION MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL LECANEMAB INJECTION MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL LECANEMAB INJECTION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL LECANEMAB INJECTION MARKET SIZE, BY PATIENT STAGE, 2024 VS 2030 (%)
FIGURE 6. GLOBAL LECANEMAB INJECTION MARKET SIZE, BY PATIENT STAGE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL LECANEMAB INJECTION MARKET SIZE, BY PATIENT AGE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL LECANEMAB INJECTION MARKET SIZE, BY PATIENT AGE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL LECANEMAB INJECTION MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 10. GLOBAL LECANEMAB INJECTION MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL LECANEMAB INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 12. GLOBAL LECANEMAB INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. AMERICAS LECANEMAB INJECTION MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 14. AMERICAS LECANEMAB INJECTION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. UNITED STATES LECANEMAB INJECTION MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 16. UNITED STATES LECANEMAB INJECTION MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. EUROPE, MIDDLE EAST & AFRICA LECANEMAB INJECTION MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. EUROPE, MIDDLE EAST & AFRICA LECANEMAB INJECTION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. ASIA-PACIFIC LECANEMAB INJECTION MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. ASIA-PACIFIC LECANEMAB INJECTION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. LECANEMAB INJECTION MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 22. LECANEMAB INJECTION MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 23. LECANEMAB INJECTION MARKET: RESEARCHAI
FIGURE 24. LECANEMAB INJECTION MARKET: RESEARCHSTATISTICS
FIGURE 25. LECANEMAB INJECTION MARKET: RESEARCHCONTACTS
FIGURE 26. LECANEMAB INJECTION MARKET: RESEARCHARTICLES

LIST OF TABLES

TABLE 1. LECANEMAB INJECTION MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL LECANEMAB INJECTION MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL LECANEMAB INJECTION MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL LECANEMAB INJECTION MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL LECANEMAB INJECTION MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL LECANEMAB INJECTION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL LECANEMAB INJECTION MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL LECANEMAB INJECTION MARKET SIZE, BY PATIENT STAGE, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL LECANEMAB INJECTION MARKET SIZE, BY PATIENT STAGE, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL LECANEMAB INJECTION MARKET SIZE, BY EARLY ALZHEIMER'S DISEASE, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL LECANEMAB INJECTION MARKET SIZE, BY EARLY ALZHEIMER'S DISEASE, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL LECANEMAB INJECTION MARKET SIZE, BY MILD COGNITIVE IMPAIRMENT, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL LECANEMAB INJECTION MARKET SIZE, BY MILD COGNITIVE IMPAIRMENT, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL LECANEMAB INJECTION MARKET SIZE, BY MODERATE ALZHEIMER'S DISEASE, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL LECANEMAB INJECTION MARKET SIZE, BY MODERATE ALZHEIMER'S DISEASE, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL LECANEMAB INJECTION MARKET SIZE, BY PATIENT AGE, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL LECANEMAB INJECTION MARKET SIZE, BY PATIENT AGE, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL LECANEMAB INJECTION MARKET SIZE, BY 60-70 YEARS, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL LECANEMAB INJECTION MARKET SIZE, BY 60-70 YEARS, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL LECANEMAB INJECTION MARKET SIZE, BY 71-80 YEARS, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL LECANEMAB INJECTION MARKET SIZE, BY 71-80 YEARS, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL LECANEMAB INJECTION MARKET SIZE, BY 81+ YEARS, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL LECANEMAB INJECTION MARKET SIZE, BY 81+ YEARS, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL LECANEMAB INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL LECANEMAB INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL LECANEMAB INJECTION MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL LECANEMAB INJECTION MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL LECANEMAB INJECTION MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL LECANEMAB INJECTION MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL LECANEMAB INJECTION MARKET SIZE, BY LONG TERM CARE FACILITIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL LECANEMAB INJECTION MARKET SIZE, BY LONG TERM CARE FACILITIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL LECANEMAB INJECTION MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL LECANEMAB INJECTION MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL LECANEMAB INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL LECANEMAB INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL LECANEMAB INJECTION MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL LECANEMAB INJECTION MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL LECANEMAB INJECTION MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL LECANEMAB INJECTION MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL LECANEMAB INJECTION MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL LECANEMAB INJECTION MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. AMERICAS LECANEMAB INJECTION MARKET SIZE, BY PATIENT STAGE, 2018-2024 (USD MILLION)
TABLE 44. AMERICAS LECANEMAB INJECTION MARKET SIZE, BY PATIENT STAGE, 2025-2030 (USD MILLION)
TABLE 45. AMERICAS LECANEMAB INJECTION MARKET SIZE, BY PATIENT AGE, 2018-2024 (USD MILLION)
TABLE 46. AMERICAS LECANEMAB INJECTION MARKET SIZE, BY PATIENT AGE, 2025-2030 (USD MILLION)
TABLE 47. AMERICAS LECANEMAB INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 48. AMERICAS LECANEMAB INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 49. AMERICAS LECANEMAB INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 50. AMERICAS LECANEMAB INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 51. AMERICAS LECANEMAB INJECTION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 52. AMERICAS LECANEMAB INJECTION MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 53. UNITED STATES LECANEMAB INJECTION MARKET SIZE, BY PATIENT STAGE, 2018-2024 (USD MILLION)
TABLE 54. UNITED STATES LECANEMAB INJECTION MARKET SIZE, BY PATIENT STAGE, 2025-2030 (USD MILLION)
TABLE 55. UNITED STATES LECANEMAB INJECTION MARKET SIZE, BY PATIENT AGE, 2018-2024 (USD MILLION)
TABLE 56. UNITED STATES LECANEMAB INJECTION MARKET SIZE, BY PATIENT AGE, 2025-2030 (USD MILLION)
TABLE 57. UNITED STATES LECANEMAB INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 58. UNITED STATES LECANEMAB INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 59. UNITED STATES LECANEMAB INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 60. UNITED STATES LECANEMAB INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 61. UNITED STATES LECANEMAB INJECTION MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 62. UNITED STATES LECANEMAB INJECTION MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 63. CANADA LECANEMAB INJECTION MARKET SIZE, BY PATIENT STAGE, 2018-2024 (USD MILLION)
TABLE 64. CANADA LECANEMAB INJECTION MARKET SIZE, BY PATIENT STAGE, 2025-2030 (USD MILLION)
TABLE 65. CANADA LECANEMAB INJECTION MARKET SIZE, BY PATIENT AGE, 2018-2024 (USD MILLION)
TABLE 66. CANADA LECANEMAB INJECTION MARKET SIZE, BY PATIENT AGE, 2025-2030 (USD MILLION)
TABLE 67. CANADA LECANEMAB INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 68. CANADA LECANEMAB INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 69. CANADA LECANEMAB INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 70. CANADA LECANEMAB INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 71. MEXICO LECANEMAB INJECTION MARKET SIZE, BY PATIENT STAGE, 2018-2024 (USD MILLION)
TABLE 72. MEXICO LECANEMAB INJECTION MARKET SIZE, BY PATIENT STAGE, 2025-2030 (USD MILLION)
TABLE 73. MEXICO LECANEMAB INJECTION MARKET SIZE, BY PATIENT AGE, 2018-2024 (USD MILLION)
TABLE 74. MEXICO LECANEMAB INJECTION MARKET SIZE, BY PATIENT AGE, 2025-2030 (USD MILLION)
TABLE 75. MEXICO LECANEMAB INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 76. MEXICO LECANEMAB INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 77. MEXICO LECANEMAB INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 78. MEXICO LECANEMAB INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 79. BRAZIL LECANEMAB INJECTION MARKET SIZE, BY PATIENT STAGE, 2018-2024 (USD MILLION)
TABLE 80. BRAZIL LECANEMAB INJECTION MARKET SIZE, BY PATIENT STAGE, 2025-2030 (USD MILLION)
TABLE 81. BRAZIL LECANEMAB INJECTION MARKET SIZE, BY PATIENT AGE, 2018-2024 (USD MILLION)
TABLE 82. BRAZIL LECANEMAB INJECTION MARKET SIZE, BY PATIENT AGE, 2025-2030 (USD MILLION)
TABLE 83. BRAZIL LECANEMAB INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 84. BRAZIL LECANEMAB INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 85. BRAZIL LECANEMAB INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 86. BRAZIL LECANEMAB INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 87. ARGENTINA LECANEMAB INJECTION MARKET SIZE, BY PATIENT STAGE, 2018-2024 (USD MILLION)
TABLE 88. ARGENTINA LECANEMAB INJECTION MARKET SIZE, BY PATIENT STAGE, 2025-2030 (USD MILLION)
TABLE 89. ARGENTINA LECANEMAB INJECTION MARKET SIZE, BY PATIENT AGE, 2018-2024 (USD MILLION)
TABLE 90. ARGENTINA LECANEMAB INJECTION MARKET SIZE, BY PATIENT AGE, 2025-2030 (USD MILLION)
TABLE 91. ARGENTINA LECANEMAB INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 92. ARGENTINA LECANEMAB INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 93. ARGENTINA LECANEMAB INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 94. ARGENTINA LECANEMAB INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 95. EUROPE, MIDDLE EAST & AFRICA LECANEMAB INJECTION MARKET SIZE, BY PATIENT STAGE, 2018-2024 (USD MILLION)
TABLE 96. EUROPE, MIDDLE EAST & AFRICA LECANEMAB INJECTION MARKET SIZE, BY PATIENT STAGE, 2025-2030 (USD MILLION)
TABLE 97. EUROPE, MIDDLE EAST & AFRICA LECANEMAB INJECTION MARKET SIZE, BY PATIENT AGE, 2018-2024 (USD MILLION)
TABLE 98. EUROPE, MIDDLE EAST & AFRICA LECANEMAB INJECTION MARKET SIZE, BY PATIENT AGE, 2025-2030 (USD MILLION)
TABLE 99. EUROPE, MIDDLE EAST & AFRICA LECANEMAB INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 100. EUROPE, MIDDLE EAST & AFRICA LECANEMAB INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 101. EUROPE, MIDDLE EAST & AFRICA LECANEMAB INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 102. EUROPE, MIDDLE EAST & AFRICA LECANEMAB INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 103. EUROPE, MIDDLE EAST & AFRICA LECANEMAB INJECTION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 104. EUROPE, MIDDLE EAST & AFRICA LECANEMAB INJECTION MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 105. UNITED KINGDOM LECANEMAB INJECTION MARKET SIZE, BY PATIENT STAGE, 2018-2024 (USD MILLION)
TABLE 106. UNITED KINGDOM LECANEMAB INJECTION MARKET SIZE, BY PATIENT STAGE, 2025-2030 (USD MILLION)
TABLE 107. UNITED KINGDOM LECANEMAB INJECTION MARKET SIZE, BY PATIENT AGE, 2018-2024 (USD MILLION)
TABLE 108. UNITED KINGDOM LECANEMAB INJECTION MARKET SIZE, BY PATIENT AGE, 2025-2030 (USD MILLION)
TABLE 109. UNITED KINGDOM LECANEMAB INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 110. UNITED KINGDOM LECANEMAB INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 111. UNITED KINGDOM LECANEMAB INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 112. UNITED KINGDOM LECANEMAB INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 113. GERMANY LECANEMAB INJECTION MARKET SIZE, BY PATIENT STAGE, 2018-2024 (USD MILLION)
TABLE 114. GERMANY LECANEMAB INJECTION MARKET SIZE, BY PATIENT STAGE, 2025-2030 (USD MILLION)
TABLE 115. GERMANY LECANEMAB INJECTION MARKET SIZE, BY PATIENT AGE, 2018-2024 (USD MILLION)
TABLE 116. GERMANY LECANEMAB INJECTION MARKET SIZE, BY PATIENT AGE, 2025-2030 (USD MILLION)
TABLE 117. GERMANY LECANEMAB INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 118. GERMANY LECANEMAB INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 119. GERMANY LECANEMAB INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 120. GERMANY LECANEMAB INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 121. FRANCE LECANEMAB INJECTION MARKET SIZE, BY PATIENT STAGE, 2018-2024 (USD MILLION)
TABLE 122. FRANCE LECANEMAB INJECTION MARKET SIZE, BY PATIENT STAGE, 2025-2030 (USD MILLION)
TABLE 123. FRANCE LECANEMAB INJECTION MARKET SIZE, BY PATIENT AGE, 2018-2024 (USD MILLION)
TABLE 124. FRANCE LECANEMAB INJECTION MARKET SIZE, BY PATIENT AGE, 2025-2030 (USD MILLION)
TABLE 125. FRANCE LECANEMAB INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 126. FRANCE LECANEMAB INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 127. FRANCE LECANEMAB INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 128. FRANCE LECANEMAB INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 129. RUSSIA LECANEMAB INJECTION MARKET SIZE, BY PATIENT STAGE, 2018-2024 (USD MILLION)
TABLE 130. RUSSIA LECANEMAB INJECTION MARKET SIZE, BY PATIENT STAGE, 2025-2030 (USD MILLION)
TABLE 131. RUSSIA LECANEMAB INJECTION MARKET SIZE, BY PATIENT AGE, 2018-2024 (USD MILLION)
TABLE 132. RUSSIA LECANEMAB INJECTION MARKET SIZE, BY PATIENT AGE, 2025-2030 (USD MILLION)
TABLE 133. RUSSIA LECANEMAB INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 134. RUSSIA LECANEMAB INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 135. RUSSIA LECANEMAB INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 136. RUSSIA LECANEMAB INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 137. ITALY LECANEMAB INJECTION MARKET SIZE, BY PATIENT STAGE, 2018-2024 (USD MILLION)
TABLE 138. ITALY LECANEMAB INJECTION MARKET SIZE, BY PATIENT STAGE, 2025-2030 (USD MILLION)
TABLE 139. ITALY LECANEMAB INJECTION MARKET SIZE, BY PATIENT AGE, 2018-2024 (USD MILLION)
TABLE 140. ITALY LECANEMAB INJECTION MARKET SIZE, BY PATIENT AGE, 2025-2030 (USD MILLION)
TABLE 141. ITALY LECANEMAB INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 142. ITALY LECANEMAB INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 143. ITALY LECANEMAB INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 144. ITALY LECANEMAB INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 145. SPAIN LECANEMAB INJECTION MARKET SIZE, BY PATIENT STAGE, 2018-2024 (USD MILLION)
TABLE 146. SPAIN LECANEMAB INJECTION MARKET SIZE, BY PATIENT STAGE, 2025-2030 (USD MILLION)
TABLE 147. SPAIN LECANEMAB INJECTION MARKET SIZE, BY PATIENT AGE, 2018-2024 (USD MILLION)
TABLE 148. SPAIN LECANEMAB INJECTION MARKET SIZE, BY PATIENT AGE, 2025-2030 (USD MILLION)
TABLE 149. SPAIN LECANEMAB INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 150. SPAIN LECANEMAB INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 151. SPAIN LECANEMAB INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 152. SPAIN LECANEMAB INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 153. UNITED ARAB EMIRATES LECANEMAB INJECTION MARKET SIZE, BY PATIENT STAGE, 2018-2024 (USD MILLION)
TABLE 154. UNITED ARAB EMIRATES LECANEMAB INJECTION MARKET SIZE, BY PATIENT STAGE, 2025-2030 (USD MILLION)
TABLE 155. UNITED ARAB EMIRATES LECANEMAB INJECTION MARKET SIZE, BY PATIENT AGE, 2018-2024 (USD MILLION)
TABLE 156. UNITED ARAB EMIRATES LECANEMAB INJECTION MARKET SIZE, BY PATIENT AGE, 2025-2030 (USD MILLION)
TABLE 157. UNITED ARAB EMIRATES LECANEMAB INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 158. UNITED ARAB EMIRATES LECANEMAB INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 159. UNITED ARAB EMIRATES LECANEMAB INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 160. UNITED ARAB EMIRATES LECANEMAB INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 161. SAUDI ARABIA LECANEMAB INJECTION MARKET SIZE, BY PATIENT STAGE, 2018-2024 (USD MILLION)
TABLE 162. SAUDI ARABIA LECANEMAB INJECTION MARKET SIZE, BY PATIENT STAGE, 2025-2030 (USD MILLION)
TABLE 163. SAUDI ARABIA LECANEMAB INJECTION MARKET SIZE, BY PATIENT AGE, 2018-2024 (USD MILLION)
TABLE 164. SAUDI ARABIA LECANEMAB INJECTION MARKET SIZE, BY PATIENT AGE, 2025-2030 (USD MILLION)
TABLE 165. SAUDI ARABIA LECANEMAB INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 166. SAUDI ARABIA LECANEMAB INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 167. SAUDI ARABIA LECANEMAB INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 168. SAUDI ARABIA LECANEMAB INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 169. SOUTH AFRICA LECANEMAB INJECTION MARKET SIZE, BY PATIENT STAGE, 2018-2024 (USD MILLION)
TABLE 170. SOUTH AFRICA LECANEMAB INJECTION MARKET SIZE, BY PATIENT STAGE, 2025-2030 (USD MILLION)
TABLE 171. SOUTH AFRICA LECANEMAB INJECTION MARKET SIZE, BY PATIENT AGE, 2018-2024 (USD MILLION)
TABLE 172. SOUTH AFRICA LECANEMAB INJECTION MARKET SIZE, BY PATIENT AGE, 2025-2030 (USD MILLION)
TABLE 173. SOUTH AFRICA LECANEMAB INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 174. SOUTH AFRICA LECANEMAB INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 175. SOUTH AFRICA LECANEMAB INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 176. SOUTH AFRICA LECANEMAB INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 177. DENMARK LECANEMAB INJECTION MARKET SIZE, BY PATIENT STAGE, 2018-2024 (USD MILLION)
TABLE 178. DENMARK LECANEMAB INJECTION MARKET SIZE, BY PATIENT STAGE, 2025-2030 (USD MILLION)
TABLE 179. DENMARK LECANEMAB INJECTION MARKET SIZE, BY PATIENT AGE, 2018-2024 (USD MILLION)
TABLE 180. DENMARK LECANEMAB INJECTION MARKET SIZE, BY PATIENT AGE, 2025-2030 (USD MILLION)
TABLE 181. DENMARK LECANEMAB INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 182. DENMARK LECANEMAB INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 183. DENMARK LECANEMAB INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 184. DENMARK LECANEMAB INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 185. NETHERLANDS LECANEMAB INJECTION MARKET SIZE, BY PATIENT STAGE, 2018-2024 (USD MILLION)
TABLE 186. NETHERLANDS LECANEMAB INJECTION MARKET SIZE, BY PATIENT STAGE, 2025-2030 (USD MILLION)
TABLE 187. NETHERLANDS LECANEMAB INJECTION MARKET SIZE, BY PATIENT AGE, 2018-2024 (USD MILLION)
TABLE 188. NETHERLANDS LECANEMAB INJECTION MARKET SIZE, BY PATIENT AGE, 2025-2030 (USD MILLION)
TABLE 189. NETHERLANDS LECANEMAB INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 190. NETHERLANDS LECANEMAB INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 191. NETHERLANDS LECANEMAB INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 192. NETHERLANDS LECANEMAB INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 193. QATAR LECANEMAB INJECTION MARKET SIZE, BY PATIENT STAGE, 2018-2024 (USD MILLION)
TABLE 194. QATAR LECANEMAB INJECTION MARKET SIZE, BY PATIENT STAGE, 2025-2030 (USD MILLION)
TABLE 195. QATAR LECANEMAB INJECTION MARKET SIZE, BY PATIENT AGE, 2018-2024 (USD MILLION)
TABLE 196. QATAR LECANEMAB INJECTION MARKET SIZE, BY PATIENT AGE, 2025-2030 (USD MILLION)
TABLE 197. QATAR LECANEMAB INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 198. QATAR LECANEMAB INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 199. QATAR LECANEMAB INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 200. QATAR LECANEMAB INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 201. FINLAND LECANEMAB INJECTION MARKET SIZE, BY PATIENT STAGE, 2018-2024 (USD MILLION)
TABLE 202. FINLAND LECANEMAB INJECTION MARKET SIZE, BY PATIENT STAGE, 2025-2030 (USD MILLION)
TABLE 203. FINLAND LECANEMAB INJECTION MARKET SIZE, BY PATIENT AGE, 2018-2024 (USD MILLION)
TABLE 204. FINLAND LECANEMAB INJECTION MARKET SIZE, BY PATIENT AGE, 2025-2030 (USD MILLION)
TABLE 205. FINLAND LECANEMAB INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 206. FINLAND LECANEMAB INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 207. FINLAND LECANEMAB INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 208. FINLAND LECANEMAB INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 209. SWEDEN LECANEMAB INJECTION MARKET SIZE, BY PATIENT STAGE, 2018-2024 (USD MILLION)
TABLE 210. SWEDEN LECANEMAB INJECTION MARKET SIZE, BY PATIENT STAGE, 2025-2030 (USD MILLION)
TABLE 211. SWEDEN LECANEMAB INJECTION MARKET SIZE, BY PATIENT AGE, 2018-2024 (USD MILLION)
TABLE 212. SWEDEN LECANEMAB INJECTION MARKET SIZE, BY PATIENT AGE, 2025-2030 (USD MILLION)
TABLE 213. SWEDEN LECANEMAB INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 214. SWEDEN LECANEMAB INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 215. SWEDEN LECANEMAB INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 216. SWEDEN LECANEMAB INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 217. NIGERIA LECANEMAB INJECTION MARKET SIZE, BY PATIENT STAGE, 2018-2024 (USD MILLION)
TABLE 218. NIGERIA LECANEMAB INJECTION MARKET SIZE, BY PATIENT STAGE, 2025-2030 (USD MILLION)
TABLE 219. NIGERIA LECANEMAB INJECTION MARKET SIZE, BY PATIENT AGE, 2018-2024 (USD MILLION)
TABLE 220. NIGERIA LECANEMAB INJECTION MARKET SIZE, BY PATIENT AGE, 2025-2030 (USD MILLION)
TABLE 221. NIGERIA LECANEMAB INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 222. NIGERIA LECANEMAB INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 223. NIGERIA LECANEMAB INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 224. NIGERIA LECANEMAB INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 225. EGYPT LECANEMAB INJECTION MARKET SIZE, BY PATIENT STAGE, 2018-2024 (USD MILLION)
TABLE 226. EGYPT LECANEMAB INJECTION MARKET SIZE, BY PATIENT STAGE, 2025-2030 (USD MILLION)
TABLE 227. EGYPT LECANEMAB INJECTION MARKET SIZE, BY PATIENT AGE, 2018-2024 (USD MILLION)
TABLE 228. EGYPT LECANEMAB INJECTION MARKET SIZE, BY PATIENT AGE, 2025-2030 (USD MILLION)
TABLE 229. EGYPT LECANEMAB INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 230. EGYPT LECANEMAB INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 231. EGYPT LECANEMAB INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 232. EGYPT LECANEMAB INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 233. TURKEY LECANEMAB INJECTION MARKET SIZE, BY PATIENT STAGE, 2018-2024 (USD MILLION)
TABLE 234. TURKEY LECANEMAB INJECTION MARKET SIZE, BY PATIENT STAGE, 2025-2030 (USD MILLION)
TABLE 235. TURKEY LECANEMAB INJECTION MARKET SIZE, BY PATIENT AGE, 2018-2024 (USD MILLION)
TABLE 236. TURKEY LECANEMAB INJECTION MARKET SIZE, BY PATIENT AGE, 2025-2030 (USD MILLION)
TABLE 237. TURKEY LECANEMAB INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 238. TURKEY LECANEMAB INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 239. TURKEY LECANEMAB INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 240. TURKEY LECANEMAB INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 241. ISRAEL LECANEMAB INJECTION MARKET SIZE, BY PATIENT STAGE, 2018-2024 (USD MILLION)
TABLE 242. ISRAEL LECANEMAB INJECTION MARKET SIZE, BY PATIENT STAGE, 2025-2030 (USD MILLION)
TABLE 243. ISRAEL LECANEMAB INJECTION MARKET SIZE, BY PATIENT AGE, 2018-2024 (USD MILLION)
TABLE 244. ISRAEL LECANEMAB INJECTION MARKET SIZE, BY PATIENT AGE, 2025-2030 (USD MILLION)
TABLE 245. ISRAEL LECANEMAB INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 246. ISRAEL LECANEMAB INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 247. ISRAEL LECANEMAB INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 248. ISRAEL LECANEMAB INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 249. NORWAY LECANEMAB INJECTION MARKET SIZE, BY PATIENT STAGE, 2018-2024 (USD MILLION)
TABLE 250. NORWAY LECANEMAB INJECTION MARKET SIZE, BY PATIENT STAGE, 2025-2030 (USD MILLION)
TABLE 251. NORWAY LECANEMAB INJECTION MARKET SIZE, BY PATIENT AGE, 2018-2024 (USD MILLION)
TABLE 252. NORWAY LECANEMAB INJECTION MARKET SIZE, BY PATIENT AGE, 2025-2030 (USD MILLION)
TABLE 253. NORWAY LECANEMAB INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 254. NORWAY LECANEMAB INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 255. NORWAY LECANEMAB INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 256. NORWAY LECANEMAB INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 257. POLAND LECANEMAB INJECTION MARKET SIZE, BY PATIENT STAGE, 2018-2024 (USD MILLION)
TABLE 258. POLAND LECANEMAB INJECTION MARKET SIZE, BY PATIENT STAGE, 2025-2030 (USD MILLION)
TABLE 259. POLAND LECANEMAB INJECTION MARKET SIZE, BY PATIENT AGE, 2018-2024 (USD MILLION)
TABLE 260. POLAND LECANEMAB INJECTION MARKET SIZE, BY PATIENT AGE, 2025-2030 (USD MILLION)
TABLE 261. POLAND LECANEMAB INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 262. POLAND LECANEMAB INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 263. POLAND LECANEMAB INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 264. POLAND LECANEMAB INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 265. SWITZERLAND LECANEMAB INJECTION MARKET SIZE, BY PATIENT STAGE, 2018-2024 (USD MILLION)
TABLE 266. SWITZERLAND LECANEMAB INJECTION MARKET SIZE, BY PATIENT STAGE, 2025-2030 (USD MILLION)
TABLE 267. SWITZERLAND LECANEMAB INJECTION MARKET SIZE, BY PATIENT AGE, 2018-2024 (USD MILLION)
TABLE 268. SWITZERLAND LECANEMAB INJECTION MARKET SIZE, BY PATIENT AGE, 2025-2030 (USD MILLION)
TABLE 269. SWITZERLAND LECANEMAB INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 270. SWITZERLAND LECANEMAB INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 271. SWITZERLAND LECANEMAB INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 272. SWITZERLAND LECANEMAB INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 273. ASIA-PACIFIC LECANEMAB INJECTION MARKET SIZE, BY PATIENT STAGE, 2018-2024 (USD MILLION)
TABLE 274. ASIA-PACIFIC LECANEMAB INJECTION MARKET SIZE, BY PATIENT STAGE, 2025-2030 (USD MILLION)
TABLE 275. ASIA-PACIFIC LECANEMAB INJECTION MARKET SIZE, BY PATIENT AGE, 2018-2024 (USD MILLION)
TABLE 276. ASIA-PACIFIC LECANEMAB INJECTION MARKET SIZE, BY PATIENT AGE, 2025-2030 (USD MILLION)
TABLE 277. ASIA-PACIFIC LECANEMAB INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 278. ASIA-PACIFIC LECANEMAB INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 279. ASIA-PACIFIC LECANEMAB INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 280. ASIA-PACIFIC LECANEMAB INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 281. ASIA-PACIFIC LECANEMAB INJECTION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 282. ASIA-PACIFIC LECANEMAB INJECTION MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 283. CHINA LECANEMAB INJECTION MARKET SIZE, BY PATIENT STAGE, 2018-2024 (USD MILLION)
TABLE 284. CHINA LECANEMAB INJECTION MARKET SIZE, BY PATIENT STAGE, 2025-2030 (USD MILLION)
TABLE 285. CHINA LECANEMAB INJECTION MARKET SIZE, BY PATIENT AGE, 2018-2024 (USD MILLION)
TABLE 286. CHINA LECANEMAB INJECTION MARKET SIZE, BY PATIENT AGE, 2025-2030 (USD MILLION)
TABLE 287. CHINA LECANEMAB INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 288. CHINA LECANEMAB INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 289. CHINA LECANEMAB INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 290. CHINA LECANEMAB INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 291. INDIA LECANEMAB INJECTION MARKET SIZE, BY PATIENT STAGE, 2018-2024 (USD MILLION)
TABLE 292. INDIA LECANEMAB INJECTION MARKET SIZE, BY PATIENT STAGE, 2025-2030 (USD MILLION)
TABLE 293. INDIA LECANEMAB INJECTION MARKET SIZE, BY PATIENT AGE, 2018-2024 (USD MILLION)
TABLE 294. INDIA LECANEMAB INJECTION MARKET SIZE, BY PATIENT AGE, 2025-2030 (USD MILLION)
TABLE 295. INDIA LECANEMAB INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 296. INDIA LECANEMAB INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 297. INDIA LECANEMAB INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 298. INDIA LECANEMAB INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 299. JAPAN LECANEMAB INJECTION MARKET SIZE, BY PATIENT STAGE, 2018-2024 (USD MILLION)
TABLE 300. JAPAN LECANEMAB INJECTION MARKET SIZE, BY PATIENT STAGE, 2025-2030 (USD MILLION)
TABLE 301. JAPAN LECANEMAB INJECTION MARKET SIZE, BY PATIENT AGE, 2018-2024 (USD MILLION)
TABLE 302. JAPAN LECANEMAB INJECTION MARKET SIZE, BY PATIENT AGE, 2025-2030 (USD MILLION)
TABLE 303. JAPAN LECANEMAB INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 304. JAPAN LECANEMAB INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 305. JAPAN LECANEMAB INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 306. JAPAN LECANEMAB INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 307. AUSTRALIA LECANEMAB INJECTION MARKET SIZE, BY PATIENT STAGE, 2018-2024 (USD MILLION)
TABLE 308. AUSTRALIA LECANEMAB INJECTION MARKET SIZE, BY PATIENT STAGE, 2025-2030 (USD MILLION)
TABLE 309. AUSTRALIA LECANEMAB INJECTION MARKET SIZE, BY PATIENT AGE, 2018-2024 (USD MILLION)
TABLE 310. AUSTRALIA LECANEMAB INJECTION MARKET SIZE, BY PATIENT AGE, 2025-2030 (USD MILLION)
TABLE 311. AUSTRALIA LECANEMAB INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 312. AUSTRALIA LECANEMAB INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 313. AUSTRALIA LECANEMAB INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 314. AUSTRALIA LECANEMAB INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 315. SOUTH KOREA LECANEMAB INJECTION MARKET SIZE, BY PATIENT STAGE, 2018-2024 (USD MILLION)
TABLE 316. SOUTH KOREA LECANEMAB INJECTION MARKET SIZE, BY PATIENT STAGE, 2025-2030 (USD MILLION)
TABLE 317. SOUTH KOREA LECANEMAB INJECTION MARKET SIZE, BY PATIENT AGE, 2018-2024 (USD MILLION)
TABLE 318. SOUTH KOREA LECANEMAB INJECTION MARKET SIZE, BY PATIENT AGE, 2025-2030 (USD MILLION)
TABLE 319. SOUTH KOREA LECANEMAB INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 320. SOUTH KOREA LECANEMAB INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 321. SOUTH KOREA LECANEMAB INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 322. SOUTH KOREA LECANEMAB INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 323. INDONESIA LECANEMAB INJECTION MARKET SIZE, BY PATIENT STAGE, 2018-2024 (USD MILLION)
TABLE 324. INDONESIA LECANEMAB INJECTION MARKET SIZE, BY PATIENT STAGE, 2025-2030 (USD MILLION)
TABLE 325. INDONESIA LECANEMAB INJECTION MARKET SIZE, BY PATIENT AGE, 2018-2024 (USD MILLION)
TABLE 326. INDONESIA LECANEMAB INJECTION MARKET SIZE, BY PATIENT AGE, 2025-2030 (USD MILLION)
TABLE 327. INDONESIA LECANEMAB INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 328. INDONESIA LECANEMAB INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 329. INDONESIA LECANEMAB INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 330. INDONESIA LECANEMAB INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 331. THAILAND LECANEMAB INJECTION MARKET SIZE, BY PATIENT STAGE, 2018-2024 (USD MILLION)
TABLE 332. THAILAND LECANEMAB INJECTION MARKET SIZE, BY PATIENT STAGE, 2025-2030 (USD MILLION)
TABLE 333. THAILAND LECANEMAB INJECTION MARKET SIZE, BY PATIENT AGE, 2018-2024 (USD MILLION)
TABLE 334. THAILAND LECANEMAB INJECTION MARKET SIZE, BY PATIENT AGE, 2025-2030 (USD MILLION)
TABLE 335. THAILAND LECANEMAB INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 336. THAILAND LECANEMAB INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 337. THAILAND LECANEMAB INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 338. THAILAND LECANEMAB INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 339. PHILIPPINES LECANEMAB INJECTION MARKET SIZE, BY PATIENT STAGE, 2018-2024 (USD MILLION)
TABLE 340. PHILIPPINES LECANEMAB INJECTION MARKET SIZE, BY PATIENT STAGE, 2025-2030 (USD MILLION)
TABLE 341. PHILIPPINES LECANEMAB INJECTION MARKET SIZE, BY PATIENT AGE, 2018-2024 (USD MILLION)
TABLE 342. PHILIPPINES LECANEMAB INJECTION MARKET SIZE, BY PATIENT AGE, 2025-2030 (USD MILLION)